Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) and Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.
Valuation & Earnings
This table compares Valion Bio, Inc. Common Stock and Nurix Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Valion Bio, Inc. Common Stock | $780,000.00 | 2.50 | -$8.88 million | ($159.25) | -0.01 |
| Nurix Therapeutics | $83.98 million | 28.09 | -$264.46 million | ($3.45) | -6.59 |
Risk and Volatility
Valion Bio, Inc. Common Stock has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations for Valion Bio, Inc. Common Stock and Nurix Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Valion Bio, Inc. Common Stock | 1 | 0 | 0 | 0 | 1.00 |
| Nurix Therapeutics | 1 | 1 | 13 | 0 | 2.80 |
Nurix Therapeutics has a consensus price target of $34.21, indicating a potential upside of 50.52%. Given Nurix Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Nurix Therapeutics is more favorable than Valion Bio, Inc. Common Stock.
Profitability
This table compares Valion Bio, Inc. Common Stock and Nurix Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Valion Bio, Inc. Common Stock | N/A | -193.17% | -67.10% |
| Nurix Therapeutics | -928.44% | -76.09% | -57.31% |
Institutional & Insider Ownership
4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 2.5% of Valion Bio, Inc. Common Stock shares are held by insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Nurix Therapeutics beats Valion Bio, Inc. Common Stock on 10 of the 14 factors compared between the two stocks.
About Valion Bio, Inc. Common Stock
Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
About Nurix Therapeutics
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Receive News & Ratings for Valion Bio Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valion Bio Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
